A Retrospective and Prospective Observational Study Reviewing Supportive Care Management of NHL Patients Treated With CHOP-14 or 21 Chemotherapy(With or Without Rituximab) (CHOP = Cyclophosphamide, Hydroxyrubicin (Adriamycin), Oncovin (Vincristine), Prednisone Chemotherapy )
This is a multi-center, international observational study of subjects receiving CHOP-14 or
CHOP-21 (with or without Rituximab) for the treatment of NHL. Approximately 100-150 sites
will contribute information on subjects treated at their institution.
To avoid geographical bias, sites will be selected to represent the spread of subjects in
each country. Each site will be initially limited to 5 retrospective subjects and 10
prospective subjects (15 subjects per site) but sites may be asked to contribute further
subjects to approximately 10 retrospective subjects and 20 prospective subjects.
Retrospective subjects may include any subject that has completed all cycles of chemotherapy
treatment prior to date of site initiation. Prospective subjects which may be considered
for the study are any subject planned for CHOP-14 or CHOP-21 (with or without Rituximab)
treatment after the site initiation visit.
Proportion of subjects who had an investigator assessed risk of FN ≥20% and received primary prophylaxis G-CSF
At the end of observational period (when all subjects completed planned chemotherapy or stopped treatment)
Australia: Human Research Ethics Committee